The Use of Polyethylene Glycol in the Pediatric Population (R01)

 

The purpose of the proposed study is to better understand the extent of pediatric accumulation of low molecular weight (LMW) species that may be found in PEG 3350 products (e.g., ethylene and diethylene glycol) and of PEG 3350 metabolites. PEG 3350 products are used in the treatment of constipation. If present in the product when administered and/or produced in the gut and absorbed, these metabolites and LMW species may accumulate in children taking PEG 3350 products -- potentially leading to adverse events. This is an important first step needed to begin to understand if PEG 3350 use contributes to adverse events in children due to the absorption of these species.

Deleted 08/14/2014 (Archived.) RFA-FD-14-088 Agency: Department of Health and Human Services
Office: Food and Drug Administration Grant 1 Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the HHS Grants Policy Statement, are allowed. 07/15/2014 This program does not have cost sharing or matching requirements. Lisa Ko
Grants Management Specialist http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-14-088.html lisa.ko@fda.hhs.gov $325,000.00 Awards up to $325,000.00